Clinical Trial

Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 11, 2023 (before its estimated March 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
In this study, we prospectively analyzed molecular subtyping through the PAM 50 test in HER2-negative (IHC1+ or 2+ (FISH/SISH-)) breast cancer patients. A phase 2 single arm study was designed to determine whether the addition of HER2-targeted treatment with treatment increases the pathologic remission rate.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-03-25; most recent amendment 2023-10-09.
Status change: Not Yet Recruiting → Recruiting 2023-10-09
Trial Details
NCT Number NCT04817540
Lead Sponsor Gangnam Severance Hospital
Conditions HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study
Enrollment 59 participants
Start Date 2021-09-01
Primary Completion 2024-03-30 (estimated)
Study Completion 2027-03-30 (estimated)
Updated on ClinicalTrials.gov 2023-10-11